H2A Clinical Core
H2A Clinical Core
批准号:
10689161
负责人:
Jim Aizire
金额:
$8.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-09 至 2025-08-31
关键词:
AdherenceAdvocateAfricaAfrica South of the SaharaAfricanAgeBehavioralClinicalComplexCountryDataData CollectionData ElementData SetDevelopmentElectronicsEnsureEuropeEvaluationGoalsHIVHepatitis B InfectionHepatitis B VirusHepatitis C virusHospitalsImageInfectionInterruptionInterviewLaboratoriesLanguageLeadLeadershipMalignant NeoplasmsMeasurementMeasuresMedicalMentorsMethodsMonitorParticipantPatientsPerformancePeriodicalsPilot ProjectsPrimary carcinoma of the liver cellsProceduresProcessProtocols documentationQuestionnairesResearchResearch PersonnelResourcesRisk FactorsRoleSchistosoma mansonii infectionSecondary toSenegalSiteStandardizationSwitzerlandTechnology TransferTelemedicineTestingTrainingUgandaUniversitiescareerchronic infectionclinical research sitecohortdata dictionarydata harmonizationdata integrationdata qualitydesignexperiencenovelquality assurancerecruitresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live
longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B
and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared
to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only
months. Proposed is an East and West African partnership between colleagues at Makerere University in
Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular
carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring
and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub-
Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments
to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by
developing local capacity and performing important research. The Consortium represents a complex
partnership between investigators, staff, hospitals, and universities in 4 countries representing East and West
Africa, Switzerland and USA, with 6 clinical sites, 4 primary laboratories, and ~20 coinvestigators speaking
English and French. The Clinical and Data Quality Core (CDQ) is designed to support the standardized
rigorous data collection, management and analysis of Consortium data. CDQ will ensure that high quality data
is rigorously collected, that assessment of clinical measurements and laboratory testing be standardized
between sites, that data harmonization be effectively performed, and that high quality analytical datasets be
produced in a timely manner. CDQ Core provides support for both Projects and to pilot projects through the
Developmental Core. Support to both the scientific and capacity development objectives ensures that
comprehensive, systematic and rigorous data collection, management and analysis in Consortium projects will
appropriately maximize resources and have a high likelihood of scientific impact.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic impact of ART on women living with HIV and their infants
-
批准号:10527632
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2022
-
负责人:Jim Aizire
-
依托单位:
H2A Clinical Core
-
批准号:10084613
-
项目类别:
-
资助金额:$8.08万
-
财政年份:2020
-
负责人:Jim Aizire
-
依托单位:
H2A Clinical Core
-
批准号:10259884
-
项目类别:
-
资助金额:$8.17万
-
财政年份:2020
-
负责人:Jim Aizire
-
依托单位:
H2A Clinical Core
-
批准号:10471413
-
项目类别:
-
资助金额:$9.22万
-
财政年份:2020
-
负责人:Jim Aizire
-
依托单位:
海外基金